1. Inicio
  2. Publicaciones
  3. Prognostic Value and Therapeutic Implication of Laparoscopic Extraperitoneal Paraaortic Staging in Locally Advanced Cervical Cancer: A Spanish Multicenter Study

Prognostic Value and Therapeutic Implication of Laparoscopic Extraperitoneal Paraaortic Staging in Locally Advanced Cervical Cancer: A Spanish Multicenter Study

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • D?az-Feijoo, B
  • Torn?, A
  • Tejerizo, A
  • Benito, V
  • Hern?ndez, A
  • Ruiz, R
  • Luna-Guibourg, R
  • Llueca, A
  • Coronado, P
  • Gilabert-Estelles, J
  • Bebia, V
  • Gil-Ib??ez, B
  • Gil-Moreno, A

Grupos

Abstract

Purpose To assess the impact of laparoscopic extraperitoneal paraaortic staging in therapeutic planning and prognosis of patients with locally advanced cervical cancer (LACC) as compared with imaging staging. Methods Retrospective multicenter study of stage IB2 and IIA2 to IVA (FIGO 2009) LACC patients who were candidates for primary chemoradiotherapy. The study (surgical) group included 634 patients undergoing laparoscopic/robotic extraperitoneal paraaortic staging treated with extended-field radiotherapy (EFRT) if lymph node involvement was confirmed. The control (imaging) group included 288 patients treated with EFRT when lymph node involvement was suspected on positron emission tomography-computed tomography scans and/or magnetic resonance imaging. Results In the study group, a median of 13 (range 9-17) lymph nodes were removed, with a rate of positive paraaortic nodes of 18%, with metastatic size <= 5 mm in 20.4% of cases. Paraaortic EFRT was administered to 18% of patients in the study group and in 58% of controls. In 34% of patients from the surgical group, EFRT was modified according to surgical findings with respect to imaging staging. The median follow-up in the study and control groups was 3.7 and 4.8 years, respectively. In both groups, the overall survival and cancer-specific disease-free survival were similar. The time interval between diagnosis and starting EFRT was 18 days longer in the study group, without differences in overall survival as compared with controls (hazard ratio 1.00, 95% confidence interval 0.998-1.005;p = 0.307). Conclusions Laparoscopic extraperitoneal paraaortic staging in LACC patients is safe and modified therapeutic planning, allowing better selection of candidates for EFRT.

Datos de la publicación

ISSN/ISSNe:
1068-9265, 1534-4681

ANNALS OF SURGICAL ONCOLOGY  Springer New York LLC

Tipo:
Article
Páginas:
2829-2839
PubMed:
32152774
Factor de Impacto:
1,764 SCImago ℠
Cuartil:
Q1 SCImago ℠

Citas Recibidas en Web of Science: 11

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Campos de Estudio

Proyectos y Estudios Clínicos

ESTUDIO DE LA ENFERMEDAD METASTASICA EN EL TEJIDO OVARICO CRIOPRESERVADO DE MUJERES CON CANCER DE MAMA

Investigador Principal: ANTONIO PELLICER MARTÍNEZ

PI08/90483 . INSTITUTO DE SALUD CARLOS III . 2009

SEGURIDAD Y RENDIMIENTO DEL DISPOSITIVO DE CAPTURA DE CÉLULAS TUMORALES METASTÁSICAS EN PACIENTES CON CÁNCER OVÁRICO AVANZADO.

Investigador Principal: SANTIAGO DOMINGO DEL POZO

MTRAP-2016-01 . 2017

SENTOV: GANGLIO CENTINELA EN CÁNCER DE OVARIO EN ESTADIO INICIAL.

Investigador Principal: VÍCTOR LAGO LEAL

SENTOV . 2017

TAC TRAS CIRUGÍA DE CITORREDUCCIÓN EN CÁNCER DE OVARIO: NUEVO MARCADOR PRONÓSTICO.

Investigador Principal: VÍCTOR LAGO LEAL

SDP-BEV-2018-01

ENSAYO CLÍNICO FASE II ALEATORIZADO, ABIERTO Y MULTICÉNTRICO, PARA DETERMINAR LA TOXICIDAD Y EFICACIA DE QUIMIOTERAPIA PRE-QUIRÚRGICA CON O SIN BEVACIZUMAB EN PACIENTES CON CÁNCER DE OVARIO AVANZADO.

Investigador Principal: ANA SANTABALLA BERTRÁN

GEICO-1205 . 2014

ENSAYO CLÍNICO FASE III, MULTICÉNTRICO ALEATORIZADO PARA COMPARAR LA EFICACIA DE LA ADICIÓN DE CIRUGÍA DE CITORREDUCCIÓN A LA QUIMIOTERAPIA FRENTE A LA QUIMIOTERAPIA EXCLUSIVA EN EL CÁNCER DE OVARIO RECIDIVADO SENSIBLE A PLATINO.

Investigador Principal: ANA SANTABALLA BERTRÁN

GEI-CIR-2011-01

ESTUDIO BIOMÉDICO DE COHORTES PROSPECTIVAS, MULTICÉNTRICO, NACIONAL, DIRIGIDO A PACIENTES CON INDICACIÓN QUIRÚRGICA DE HISTERECTOMÍA, MIOMECTOMÍA LAPAROSCÓPICA O LAPAROTÓMICA POR DIAGNÓSTICO DE TUMORES MIOMETRIALES (LEIOMIOMA/LEIOMIOSARCOMA).

Investigador Principal: JAVIER MONLEÓN SANCHO

IGX1-MYO-CS-19-03 . 2021

ESTUDIO BIOMÉDICO DE COHORTES PROSPECTIVAS, UNICÉNTRICO, NACIONAL, DIRIGIDO A PACIENTES CON INDICACIÓN QUIRÚRGICA POR SOSPECHA DE CÁNCER OVÁRICO.

Investigador Principal: SANTIAGO DOMINGO DEL POZO

IGX1-COV-CS-19-05 . 2021

Cita

Compartir